Acceptance Sampling Plans by Attributes

  • Harry Yang
  • David Carlin
Chapter

Abstract

As the field of quality control enters the next millennium, many pharmaceutical and biotechnology companies have striven to achieve quality in the drug and biologic products they manufacture. This is due in part to increasing public demand for products to be free of defects, as well as the 1987 publication by the international organization for standardization (commonly referred to as ISO) of the ISO 9000 series of standards for quality management and quality assurance. The ISO 9000 standards provide guidance for manufacturers to implement effective quality systems. They are also widely used by customers as a yardstick to measure the adequacy of the producer’s quality system. Manufacturers are motivated to be certified by registrars accredited by the ISO so as to enhance potential customer confidence in the quality of their products. An excellent review of ISO 9000 was given by Rabbitt and Bergh (1997). In 1994, the United States Congress passed the current Good Manufacturing Practice (cGMP) Act initiated by the Food and Drug Administration (1995). Since then, lawsuits have been filed by the FDA against a few pharmaceutical companies for failing to appropriately implement cGMP guidelines in their product release. The legal actions added a new tempo to the improvement of producers’ quality systems. As one of the key elements in the ISO 9000 standards and an integral part of the cGMP, acceptance sampling inspection before the distribution of a product lot is mandated by law.

Keywords

Sampling Plan Acceptance Sampling Acceptance Number Defective Unit Acceptance Sampling Plan 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Barr, D.B. and Dolecek, G.R. (1996). Out-of-specification laboratory results in the production of pharmaceuticals. Pharmaceutical Technology April, 5461.Google Scholar
  2. Berger, J. (1985). Statistical Decision Theory and Bayesian Analysis, Second edition. Springer-Verlag, New York.MATHCrossRefGoogle Scholar
  3. Food and Drug Administration (1995). Current good manufacturing practice in manufacturing, processing, packing, or holding of drug: Amendment of certain requirements for fmished pharmaceuticals. Federal Registry 60 (13), 4087–4091.Google Scholar
  4. Krause, A. and Olson, M. (1997). The Basics of S and S-PLUS. Springer-Verlag, New York.MATHCrossRefGoogle Scholar
  5. MathSoft Inc. (1998). S-PLUS: Programmer’s Guide, Version 4.0. MathSoft, Inc., Data Analysis Products Division, Seattle, WA.Google Scholar
  6. Rabbitt, J.T. and Bergh, P.A. (1997). The ISO 9000 Book—A Global Competitor’s Guide to Compliance & Certification. Quality Resources, White Planes, New York.Google Scholar
  7. Schilling, E.G. (1982). Acceptance Sampling in Quality Control. Marcel Dekker, New York.MATHGoogle Scholar
  8. Vogel, P.F. (1993). Evaluating out-of-specification laboratory results. Journal of Parenteral Science and Technology 47, 277–280.Google Scholar
  9. Wadsworth, H.M., Stephens, K.S., and Godfrey, A.B. (1986). Modern Methods for Quality Control and Improvement. Wiley, New York.Google Scholar
  10. Wald, A. (1947). Sequential Analysis. Wiley, New York.MATHGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Harry Yang
    • 1
  • David Carlin
    • 1
  1. 1.MedImmune, Inc.GaithersburgUSA

Personalised recommendations